3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Lymphoma, T-Cell
4
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Recurrence
2
Lymphoma, T-Cell, Peripheral
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Follicular
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
58
Dexamethasone
50
Rituximab
39
Peripheral Blood Stem Cell Transplantation
29
Paclitaxel
29
Lenalidomide
28
fludarabine phosphate
27
Gemcitabine
26
Etoposide
26
Bortezomib
26
Cytarabine
25
Busulfan
24
pembrolizumab
21
Radiotherapy
21
Bevacizumab
21
Carboplatin
20
Mycophenolic Acid
19
Melphalan
19
Cisplatin
19
Filgrastim
18
pomalidomide
17
fludarabine
17
Oxaliplatin
17
Antilymphocyte Serum
17
Cyclosporine
16
Tacrolimus
15
Methotrexate
15
Whole-Body Irradiation
14
Methylprednisolone
13
Bendamustine Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrence
×
duvelisib
×
Clear all
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts
NCT03370185
2023-02-28
BRIO
SecuraBio
Phase 2
Withdrawn